Timing of initiation and race appear to play a role in who may benefit

Women in midlife with vasomotor symptoms who initiated menopausal hormone therapy, or MHT, during perimenopause or shortly after menopause had a 22% lower risk for CVD, new data…

Timing of initiation and race appear to play a role in who may benefit